{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:36:38Z","timestamp":1790796998005,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.hoc.2025.05.012","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T03:07:31Z","timestamp":1753931251000},"page":"917-934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Measurable\/Minimal Residual Disease"],"prefix":"10.1016","volume":"39","author":[{"given":"Andrew","family":"Rawstron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2025.05.012_bib1","unstructured":"Research CfDEa. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment. 2020; Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/hematologic-malignancies-regulatory-considerations-use-minimal-residual-disease-development-drug-and (Accessed 20 April 2025)."},{"key":"10.1016\/j.hoc.2025.05.012_bib2","series-title":"WHO classification of tumours editorial board","article-title":"Monoclonal B-cell lymphocytosis","author":"Rawstron","year":"2024"},{"issue":"25","key":"10.1016\/j.hoc.2025.05.012_bib3","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.012_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.012_bib5","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.hoc.2025.05.012_bib6","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1182\/blood.2020010146","article-title":"Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.012_bib7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3324\/haematol.2013.099796","article-title":"The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy","volume":"99","author":"Santacruz","year":"2014","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.hoc.2025.05.012_bib8","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1182\/blood-2013-11-538116","article-title":"Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL","volume":"123","author":"Strati","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.012_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.hoc.2025.05.012_bib10","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood-2016-05-714162","article-title":"Minimal residual disease is an independent predictor for 10-year survival in CLL","volume":"128","author":"Kwok","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.012_bib11","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.hoc.2025.05.012_bib12","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","article-title":"Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL study group","volume":"34","author":"Kovacs","year":"2016","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.hoc.2025.05.012_bib13","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.012_bib14","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/sj.leu.2404584","article-title":"International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia","volume":"21","author":"Rawstron","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.012_bib15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1200\/JCO.24.01192","article-title":"End point surrogacy in first-line chronic lymphocytic leukemia","volume":"43","author":"Simon","year":"2025","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2025.05.012_bib16","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.2023020158","article-title":"Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up","volume":"142","author":"Thompson","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.012_bib17","doi-asserted-by":"crossref","first-page":"E168","DOI":"10.1002\/ajh.26483","article-title":"Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: a comprehensive assessment of prognostic factors","volume":"97","author":"Allsup","year":"2022","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.012_bib18","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/s41375-021-01241-1","article-title":"Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations","volume":"35","author":"Wierda","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.012_bib19","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol"},{"issue":"34","key":"10.1016\/j.hoc.2025.05.012_bib20","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.012_bib21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.012_bib22","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow- up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"Furstenau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.hoc.2025.05.012_bib23","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"issue":"30","key":"10.1016\/j.hoc.2025.05.012_bib24","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.012_bib25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.hoc.2025.05.012_bib26","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.012_bib27","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.012_bib28","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/s41375-020-01009-z","article-title":"Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia","volume":"35","author":"Letestu","year":"2021","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.hoc.2025.05.012_bib29","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood.2019001077","article-title":"Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy","volume":"134","author":"Thompson","year":"2019","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.hoc.2025.05.012_bib30","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.012_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/2643-3230.BCD-24-0292","article-title":"Minimal residual disease as an early endpoint for accelerated Drug approval in myeloma: a roadmap","volume":"6","author":"Landgren","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.012_bib32","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood-2024-205697","article-title":"Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-na\u00efve chronic lymphocytic leukemia: 5-year follow up, retreatment outcomes, and impact of MRD kinetics (\u0394MRD400)","volume":"144","author":"Soumerai","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.012_bib33","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2504341","article-title":"Measurable residual disease-guided therapy for chronic lymphocytic leukemia","author":"Munir","year":"2025","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.012_bib34","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2023-187943","article-title":"Using peripheral blood (PB) measurable residual disease (MRD) levels to predict <0.01% bone marrow disease (BM uMRD4): identification of effective PB targets for CLL treatment cessation in the ibrutinib+venetoclax arm of the FLAIR trial","volume":"142","author":"Rawstron","year":"2023","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.hoc.2025.05.012_bib35","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.2217\/fon-2022-0456","article-title":"MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"18","author":"Ryan","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.hoc.2025.05.012_bib36","unstructured":"RESOLVE MRD guided treatment, RESOLVE; 2025. Avaailable at: https:\/\/resolve-leukemia.eu\/."},{"issue":"1","key":"10.1016\/j.hoc.2025.05.012_bib37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2141.2008.07394.x","article-title":"Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)","volume":"144","author":"Schweighofer","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.012_bib38","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/bjh.18427","article-title":"Obinutuzumab as consolidation after chemo-immunotherapy: results of the UK national cancer research institute phase II\/III GALACTIC trial","volume":"199","author":"Munir","year":"2022","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.hoc.2025.05.012_bib39","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1182\/bloodadvances.2024015180","article-title":"Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION\/HO141 trial","volume":"9","author":"Niemann","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.012_bib40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/cyto.b.21595","article-title":"Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European research initiative on CLL (ERIC) & European society for clinical cell analysis (ESCCA) harmonisation project","volume":"94","author":"Rawstron","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.012_bib41","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/sj.leu.2404416","article-title":"Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens","volume":"20","author":"Rawstron","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.012_bib42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V98.1.29","article-title":"Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy","volume":"98","author":"Rawstron","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.012_bib43","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/leu.2012.216","article-title":"Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL","volume":"27","author":"Rawstron","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.012_bib44","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/leu.2015.313","article-title":"A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study","volume":"30","author":"Rawstron","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.012_bib45","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.18802","article-title":"Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia","volume":"202","author":"Nguyen","year":"2023","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.012_bib46","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/ajh.27604","article-title":"Novel flow cytometric antibody panel and dedicated analysis algorithm for automated fully standardized minimal residual disease detection in chronic lymphocytic leukemia","volume":"100","author":"Engelmann","year":"2025","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.012_bib47","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/cyto.b.21875","article-title":"Performance of eight-color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples","volume":"98","author":"Bento","year":"2020","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.012_bib48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/cyto.b.21953","article-title":"14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL\/SLL","volume":"100","author":"Goshaw","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.hoc.2025.05.012_bib49","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1080\/10428194.2021.1919658","article-title":"A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia","volume":"10","author":"Bazinet","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.012_bib50","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41375-022-01604-2","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL","volume":"36","author":"Agathangelidis","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.012_bib51","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2006-03-012948","article-title":"Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations","volume":"109","author":"Stamatopoulos","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.012_bib52","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.20040544","article-title":"Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia","volume":"200","author":"Messmer","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.hoc.2025.05.012_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.894419","article-title":"Characterizing features of human circulating B cells carrying CLL-like stereotyped immunoglobulin rearrangements","volume":"12","author":"Bagnara","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.012_bib54","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/sj.leu.2403478","article-title":"Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation","volume":"18","author":"B\u00f6ttcher","year":"2004","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.012_bib55","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2025.05.012_bib56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/978-1-0716-4188-0_8","article-title":"MRD detection in B-cell non-hodgkin lymphomas using ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR and ddPCR","volume":"2865","author":"Pott","year":"2025","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.012_bib57","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.012_bib58","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood.2022017411","article-title":"Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL","volume":"141","author":"Hengeveld","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.012_bib59","unstructured":"Adaptive Biotechnologies clonoSEQ Assay: 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION expansion of indication for use to include CLL;2025. Available at: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf20\/K200009.pdf."},{"issue":"4","key":"10.1016\/j.hoc.2025.05.012_bib60","doi-asserted-by":"crossref","first-page":"485","DOI":"10.5858\/arpa.2020-0457-OA","article-title":"Assessment of clonotypic rearrangements and minimal residual disease in lymphoid malignancies","volume":"146","author":"Hussaini","year":"2022","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.012_bib61","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41375-024-02158-1","article-title":"Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia","volume":"38","author":"Tettero","year":"2024","journal-title":"Leukemia"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882500084X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882500084X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:49:55Z","timestamp":1760503795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985882500084X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S088985882500084X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.012","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measurable\/Minimal Residual Disease","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}